10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.622.0609

IL29 Antibody (Center) Blocking Peptide

Synthetic peptide
Catalog # BP1709b

Specification

IL29 Antibody (Center) Blocking Peptide - Product Information

Primary Accession Q8IU54

IL29 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 282618

Other Names
Interferon lambda-1, IFN-lambda-1, Cytokine Zcyto21, Interleukin-29, IL-29, IFNL1, IL29, ZCYTO21

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP1709b was selected from the Center region of human IL29. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

IL29 Antibody (Center) Blocking Peptide - Protein Information

Name IFNL1

IL29 Antibody (Center) Blocking Peptide - Background

IL29 is a cytokine distantly related to type I interferons and the IL-10 family. This gene, interleukin 28A (IL28A), and interleukin 28B (IL28B) are three closely related cytokine genes that form a cytokine gene cluster on a chromosomal region mapped to 19q13. Expression of the cytokines encoded by thethree genes can be induced by viral infection. All three cytokines have been shown to interact with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor, alpha (IL28RA).

IL29 Antibody (Center) Blocking Peptide - References

Kotenko, S.V., et al., Nat. Immunol. 4(1):69-77 (2003).Sheppard, P., et al., Nat. Immunol. 4(1):63-68 (2003).

Synonyms IL29, ZCYTO21

Function
Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression.

Cellular Location
Secreted.

IL29 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides